Abstract：
PURPOSE:This is a retrospective review of our experience using high-dose-rate (HDR) brachytherapy boost for prostate cancer. METHODS AND MATERIALS:During the study period, we recommended external beam radiotherapy (45 Gy) and HDR boost (18 Gy in three fractions) combined with hormonal therapy (HT) for 2 months before and during radiotherapy to patients with at least one of the following risk features: pretreatment prostate-specific antigen>10, Gleason score (GS)>or=7, and clinical T3 disease. Additional HT for 2 years after radiotherapy was recommended for patients with GS>7. To patients whose risk of positive nodes exceeded 15%, we recommended whole pelvic radiotherapy. We administered HDR via single implant, and all fractions were given within 24h. RESULTS:This report is based on our initial 64 patients treated with HDR boost. The median follow-up was 50 months (range 25-68 months). The 4-year estimates of overall and disease-free survival were 98% and 92%, respectively. One patient experienced late grade 4 gastrointestinal toxicity. CONCLUSIONS:HDR brachytherapy is an effective means of delivering conformal prostate radiotherapy, and may be used with whole pelvic radiotherapy and HT.
journal_name
Brachytherapyjournal_title
Brachytherapyauthors
Hsu IC,Cabrera AR,Weinberg V,Speight J,Gottschalk AR,Roach M 3rd,Shinohara Kdoi
10.1016/j.brachy.2005.03.005keywords:
subject
Has Abstractpub_date
2005-01-01 00:00:00pages
202-6issue
3eissn
1538-4721issn
1873-1449pii
S1538-4721(05)00098-Xjournal_volume
4pub_type
杂志文章相关文献
Brachytherapy文献大全abstract：PURPOSE:Stereotactic body radiotherapy (SBRT) is being used with increasing frequency as definitive treatment of early stage prostate cancer. Much of the justification for its adoption was derived from earlier clinical results using high-dose-rate (HDR) brachytherapy. We determine whether HDR's dosimetry can be achieve...
journal_title：Brachytherapy
pub_type： 临床试验,杂志文章
doi：10.1016/j.brachy.2013.03.003
更新日期：2013-09-01 00:00:00
abstract：PURPOSE:We sought to develop an activity nomogram for magnetic resonance (MR)-planned permanent seed prostate brachytherapy to improve quality assurance through a secondary dosimetric check. METHODS AND MATERIALS:Patients undergoing MRI-assisted radiosurgery (MARS), whereby MRI is used for preoperative planning and po...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2019.10.002
更新日期：2020-01-01 00:00:00
abstract：PURPOSE:To quantify the percentage doses received by salivary glands (SGDs) in head and neck interstitial brachytherapy (BT). METHODS AND MATERIALS:The study included 43 patients who underwent high-dose rate iridium-192 implant for oral cavity and oropharyngeal lesions treated with BT as a boost. BT dose varied with d...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2010.03.001
更新日期：2011-01-01 00:00:00
abstract：PURPOSE:Education and training on prostate brachytherapy for radiation oncology and medical physics residents in the United States is inadequate, resulting in fewer competent radiation oncology personnel to perform implants, and is a factor in the subsequent decline of an important, potentially curative cancer treatmen...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2020.10.001
更新日期：2020-01-01 00:00:00
abstract：PURPOSE:Patients with cervical and vaginal cancer sometimes have a less straightforward approach for choice of brachytherapy treatment owing to the tumor's location and clinical presentation. The staff at Royal Brisbane & Women's Hospital in Queensland, Australia, is trying to solve this problem by the use of an old te...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2014.10.004
更新日期：2015-03-01 00:00:00
abstract：PURPOSE:Certain subsets of patients have an increased risk of all-cause mortality when androgen deprivation therapy (ADT) is used with definitive radiotherapy. We evaluated the relationship between pretreatment serum testosterone, age, and comorbidities on survival after prostate brachytherapy in men treated with and w...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2009.06.008
更新日期：2010-01-01 00:00:00
abstract：OBJECTIVE:The aim of the study is to compare the results of the combined external beam radiotherapy (EBRT) with iodine-125 seed brachytherapy vs. brachytherapy alone for prostate cancer treatment in patients with intermediate and high risk of disease recurrence. METHODS AND MATERIALS:Ninety-six patients were treated f...
journal_title：Brachytherapy
pub_type： 临床试验,杂志文章
doi：10.1016/j.brachy.2009.07.011
更新日期：2010-10-01 00:00:00
abstract：PURPOSE:To describe the use of dual source strength implants for focal low-dose-rate brachytherapy. METHODS AND MATERIALS:An interneedle dual source strength planning strategy is described for focal low-dose-rate brachytherapy of the prostate. The implanted treatment plans were designed using peripheral (except near t...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2016.04.388
更新日期：2016-09-01 00:00:00
abstract：PURPOSE:To evaluate the effectiveness of the single-energy metal artifact reduction (SEMAR) technique for improving the accuracy of I-125 seed identification in postimplant computed tomography (CT) after prostate brachytherapy. METHODS AND MATERIALS:Postimplant CT images of 40 patients treated with I-125 prostate brac...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2016.07.006
更新日期：2016-01-01 00:00:00
abstract：PURPOSE:If a prostate cancer patient treated with (125)I brachytherapy dies within 12 months after the treatment, prostate removal before cremation is recommended to avoid problems related to radioactivity in the ashes, such as inhalation of airborne particulate matter by crematorium staff or nearby residents. To provi...
journal_title：Brachytherapy
pub_type： 杂志文章,评审
doi：10.1016/j.brachy.2014.08.043
更新日期：2015-03-01 00:00:00
abstract：PURPOSE:To compare clinical outcomes between low-dose-rate (LDR) brachytherapy and high-dose-rate (HDR) brachytherapy for cervical cancer patients. METHODS AND MATERIALS:All consecutive newly diagnosed cervical cancer patients undergoing pretreatment 18-fluorodeoxyglucose positron emission tomography imaging and treat...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2018.11.008
更新日期：2019-01-01 00:00:00
abstract：PURPOSE:The British Columbia Cancer Agency has been performing iodine-125 prostate brachytherapy since 1998, initially using loose seeds and phasing into the exclusive use of RAPIDStrand (RS) (Oncura Inc., Plymouth Meeting, PA) by November 2000. The aim of this study was to investigate rates of biochemical no evidence ...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2011.01.011
更新日期：2011-11-01 00:00:00
abstract：PURPOSE:Urethral strictures are a rare complication of prostate brachytherapy (BXT), with prior studies showing radiation dose to the bulbomembranous urethra as being associated with stricture formation. This retrospective case-control study explored clinical and dosimetric parameters associated with the development of...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2017.04.242
更新日期：2017-01-01 00:00:00
abstract：PURPOSE:TG43 does not account for a lack of scatter and tissue and applicator heterogeneities. The advanced collapsed-cone engine (ACE) algorithm available for use in the Oncentra Brachy treatment planning system (Elekta AB, Stockholm, Sweden) can model these conditions more accurately and is evaluated for esophageal a...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2020.09.006
更新日期：2020-10-15 00:00:00
abstract：OBJECTIVE:To determine the usefulness of prostate-specific antigen (PSA) percentage (vs. pretreatment value assumed as 100%) in prediction of biochemical relapse, after iodine-125 ((125)I) permanent brachytherapy for prostate cancer, to employ a parameter independent by the initial PSA amount and by the individual pros...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2011.08.008
更新日期：2012-07-01 00:00:00
abstract：PURPOSE:With an aim to evaluate and report high dose date interstitial brachytherapy (HDR-ISBT) in vulvar cancers, we undertook this retrospective analysis. METHODS AND MATERIALS:Histologically proven vulvar cancers treated with HDR-ISBT between 2001 and 2016 were analyzed. Radiotherapy details, clinical outcome in te...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2016.10.003
更新日期：2017-01-01 00:00:00
abstract：PURPOSE:To develop a dose verification tool for high-dose-rate interstitial brachytherapy treatment planning in accelerated partial breast irradiation. METHODS AND MATERIALS:We have developed a software tool for interstitial brachytherapy treatment planning assessment. The software contains a database of seven (192)Ir...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2012.03.008
更新日期：2012-09-01 00:00:00
abstract：PURPOSE:To investigate the feasibility of in vivo dosimetry using microMOSFET dosimeters in patients treated with brachytherapy using two types of gynecological applicators. METHODS AND MATERIALS:In this study, a microMOSFET was placed in an empty needle of an Utrecht Interstitial Fletcher applicator or MUPIT (Martine...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2017.04.240
更新日期：2018-01-01 00:00:00
abstract：OBJECTIVES:To evaluate the interim outcomes of low-dose-rate permanent brachytherapy (PB) combined with short-term androgen deprivation therapy (ADT) in Japanese men with intermediate-risk prostate cancer excluding those with a Gleason score of 4+3. METHODS:The Protocol-intermediate-risk group (Protocol-IRG) was defin...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2014.09.001
更新日期：2015-03-01 00:00:00
abstract：PURPOSE:The aim of this study was to compare the organ-at-risk doses to the rectum and the bladder in postoperative endometrial cancer patients who receive high-dose-rate vaginal brachytherapy (HDR-VB), when using three different methods of treatment planning: (Workflow A) individualized treatment planning before every...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2016.11.008
更新日期：2017-01-01 00:00:00
abstract：PURPOSE:To analyze the dosimetric impact and periprocedural outcomes with a bioabsorbable hydrogel rectal spacer injected during low-dose-rate (LDR) prostate brachytherapy implants. METHODS AND MATERIALS:A consecutive series of 80 patients implanted with stranded I-125 LDR brachytherapy seeds were evaluated, of which ...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2019.11.002
更新日期：2020-01-01 00:00:00
abstract：PURPOSE:To compare a standard radio-oncological and a surgical biochemical failure definition after combined-modality radiation therapy (CRT) in men with intermediate- and high-risk prostate cancer. METHODS:425 men were treated with external beam radiotherapy (59.4 Gy, 33 fractions) and 125J seed-brachytherapy (S-BT, ...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2019.09.001
更新日期：2020-01-01 00:00:00
abstract：PURPOSE:For selected early breast cancers, intraoperative radiation therapy (IORT) at the time of lumpectomy can be an efficient alternative to fractionated whole breast radiation therapy (WBRT). However, some patients are later recommended WBRT after IORT due to surgical pathologic findings. To understand risk factor ...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2016.09.012
更新日期：2017-01-01 00:00:00
abstract：PURPOSE:Accurate patient-specific dosimetry in intravascular brachytherapy (IVBT) is generally difficult due to the extremely high-dose gradient, complexity of treatment device, and patient-specific geometry (e.g., calcification, stent, curvature, movement of target). The purpose of this study is to analyze quantitativ...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2005.07.004
更新日期：2005-01-01 00:00:00
abstract：UNLABELLED:PURPOSE/INTRODUCTION: To safely irradiate retroperitoneal targets as paraaortic lymph node by separating abdominal at-risk organs from the target during irradiation, we created a percutaneous paravertebral approach of high-dose-rate brachytherapy with hyaluronate gel injection (HGI). We report a case treated...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2011.12.004
更新日期：2013-01-01 00:00:00
abstract：PURPOSE:Accelerated partial breast irradiation (APBI) continues to increase in popularity. Up to 14% of patients treated with the MammoSite (MS) report some degree of chronic pain, which may be related to chest wall toxicity. Reports from several institutions using the multicatheter (MC) technique have not shown associ...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2008.11.007
更新日期：2009-04-01 00:00:00
abstract：PURPOSE:To investigate Axxent (iCAD, Inc., San Jose, CA) electronic brachytherapy balloon deformation and its dosimetric impact because of an external flexible shield (FlexiShield [FS]; iCAD, Inc.). METHODS AND MATERIALS:Prostheses breast tissue phantom overlaid three spherical balloon applicators to simulate three cl...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2017.01.009
更新日期：2017-01-01 00:00:00
abstract：BACKGROUND AND PURPOSE:Esophageal neoplasm has a poor prognosis, and palliative care remains an important goal of treatment. The purpose of this study was to assess the ability of high-dose-rate brachytherapy (HDRB) to improve dysphagia in 115 patients treated at our institution. METHODS AND MATERIALS:Patients previou...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2014.09.007
更新日期：2015-01-01 00:00:00
abstract：PURPOSE:High-dose-rate (HDR) brachytherapy boost is a treatment of intermediate- to high-risk prostate cancer, but long-term clinical outcome data are sparse. We report long-term survival and toxicity data in a cohort of patients treated in a single institution. METHODS:Between 1998 and 2004, 654 patients with localiz...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2019.01.013
更新日期：2019-01-01 00:00:00
abstract：PURPOSE:The study aimed to evaluate mature outcomes of a Phase I/II high-dose-rate brachytherapy (HDRB) boost protocol. METHODS AND MATERIALS:We analyzed data from 88 patients with T1a-T3a, N0, M0 prostate adenocarcinoma treated on a prospective Phase I/II HDRB boost protocol of 16 (n = 47) or 20 Gy (n = 41) in four f...
journal_title：Brachytherapy
pub_type： 杂志文章
doi：10.1016/j.brachy.2006.08.007
更新日期：2006-10-01 00:00:00
